RONG
Lv52
980 积分
2025-01-05 加入
-
HER2 testing: evolution and update for a companion diagnostic assay
43分钟前
求助中
-
From whole-slide image to biomarker prediction: end-to-end weakly supervised deep learning in computational pathology
19小时前
已完结
-
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer
7天前
已完结
-
Global alliances in translational cancer research
8天前
已完结
-
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
8天前
已关闭
-
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
8天前
已完结
-
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
13天前
已完结
-
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
13天前
已完结
-
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
15天前
已完结
-
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
15天前
已完结